Trial Testing ALZ-101 Alzheimer’s Vaccine Recruits First Patient

Trial Testing ALZ-101 Alzheimer’s Vaccine Recruits First Patient

311828

Trial Testing ALZ-101 Alzheimer’s Vaccine Recruits First Patient

The first patient has been recruited, in Finland, for Alzinova AB’s Phase 1b clinical trial testing its ALZ-101 vaccine for Alzheimer’s disease, the company announced. Alzinova AB, a Swedish biopharma company, is working to develop treatments for Alzheimer’s that specifically target amyloid-beta oligomers — chains of several single units (monomers) of the protein. The toxic aggregation, or buildup, in the brain of these oligomers leads to the disease’s clinical manifestations. “It is very satisfying that…

You must be logged in to read/download the full post.